IGC Pharma (IGC) Stock Price, News & Analysis

Company Overview

IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Key Stats

• Today's Range: $0.40 to $0.43
• 50-Day Range: N/A
• 52-Week Range: $0.25 to $0.50
• Volume: 413,783 shs
• Average Volume: 1.28 million shs
• Market Capitalization: $38.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Buy

IGC Pharma Stock Analysis - MarketRank™

IGC Pharma scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

IGC Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

IGC Pharma has a consensus price target of $4.50, representing about 981.0% upside from its current price of $0.42.

Amount of Analyst Coverage

IGC Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of IGC Pharma is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IGC Pharma is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IGC Pharma has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.31% of the float of IGC Pharma has been sold short.

Short Interest Ratio / Days to Cover

IGC Pharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IGC Pharma has recently decreased by 17.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IGC Pharma does not currently pay a dividend.

Dividend Growth

IGC Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.31% of the float of IGC Pharma has been sold short.

Short Interest Ratio / Days to Cover

IGC Pharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IGC Pharma has recently decreased by 17.64%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for IGC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IGC Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.66% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 3.87% of the stock of IGC Pharma is held by institutions.

IGC Stock Analysis - Frequently Asked Questions

How have IGC shares performed this year?

IGC Pharma's stock was trading at $0.39 on January 1st, 2025. Since then, IGC shares have increased by 6.7% and is now trading at $0.4163.

How do I buy shares of IGC Pharma?

Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IGC Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray Brands (TLRY), Cronos Group (CRON), Micron Technology (MU) and NewAge (NBEV).

Company Calendar

• Today: 9/15/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:IGC
• CIK: 1326205
• Web: N/A
• Phone: (301) 983-0998
• Fax: 240-465-0273
• Employees: 61
• Year Founded: N/A

Price Target and Rating

• Average Price Target for IGC Pharma: $4.50
• High Price Target: $4.50
• Low Price Target: $4.50
• Potential Upside/Downside: +1,008.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.12 million
• Net Margins: -478.82%
• Pretax Margin: -477.92%
• Return on Equity: -97.59%
• Return on Assets: -70.33%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 1.25
• Quick Ratio: 0.47

Sales & Book Value

• Annual Sales: $1.27 million
• Price / Sales: 29.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 5.07

Miscellaneous

• Outstanding Shares: 90,810,000
• Free Float: 69,324,000
• Market Cap: $36.86 million
• Optionable: N/A
• Beta: 1.08